MRSN icon

Mersana Therapeutics

1.60 USD
-0.14
8.05%
At close Dec 20, 4:00 PM EST
After hours
1.55
-0.05
3.13%
1 day
-8.05%
5 days
-25.58%
1 month
-27.93%
3 months
-25.93%
6 months
-21.57%
Year to date
-29.52%
1 year
-16.23%
5 years
-65.81%
10 years
-88.57%
 

About: Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Employees: 123

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

15% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 33

0.38% more ownership

Funds ownership: 95.19% [Q2] → 95.58% (+0.38%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

5% less funds holding

Funds holding: 122 [Q2] → 116 (-6) [Q3]

5% less capital invested

Capital invested by funds: $234M [Q2] → $222M (-$12.5M) [Q3]

32% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 19

37% less call options, than puts

Call options by funds: $770K | Put options by funds: $1.23M

Research analyst outlook

We haven’t received any recent analyst ratings for MRSN.

Financial journalist opinion

Positive
Seeking Alpha
2 days ago
Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable
Mersana Therapeutics is developing novel antibody-drug conjugates targeting a heretofore untapped immune checkpoint, as well as HER2 from another angle. The company has an operational runway of 6-7 quarters excluding collaboration revenues. The promise of phase 1 trial data gives us a chance to see if Mersana's ADC platform can make drugs that are more tolerable than those being developed by competitors.
Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable
Neutral
Seeking Alpha
1 month ago
Mersana Therapeutics, Inc. (MRSN) Q3 2024 Earnings Call Transcript
Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Jason Fredette - SVP, IR Martin Huber - President & CEO Mohan Bala - SVP, Chief Development Officer Brian DeSchuytner - CFO & COO Conference Call Participants Tara Bancroft - TD Cowen Yen-Der Li - Leerink Partners Charles Zhu - LifeSci Capital Ashiq Mubarack - Citi Yige Guo - Guggenheim Justin Zelin - BTIG Operator Good morning, and welcome to Mersana Therapeutics Third Quarter 2024 Conference Call. Currently all participants are in listen-only mode.
Mersana Therapeutics, Inc. (MRSN) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.35 per share a year ago.
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results
CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the third quarter ended September 30, 2024.
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results
Neutral
GlobeNewsWire
1 month ago
Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2024 on Wednesday, November 13, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024
Neutral
Seeking Alpha
4 months ago
Mersana Therapeutics, Inc. (MRSN) Q2 2024 Earnings Call Transcript
Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q2 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Martin Huber - President & CEO Brian DeSchuytner - CFO & COO Jason Fredette - SVP, IR Conference Call Participants Tara Bancroft - TD Cowen Jonathan Chang - Leerink Partners Ashiq Mubarack - Citi Michael Schmidt - Guggenheim Charles Zhu - LifeSci Capital Colleen Kusy - Robert W. Baird Brian Cheng - J.P.
Mersana Therapeutics, Inc. (MRSN) Q2 2024 Earnings Call Transcript
Negative
Zacks Investment Research
4 months ago
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.47 per share a year ago.
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates
Neutral
GlobeNewsWire
4 months ago
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter ended June 30, 2024.
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
Neutral
GlobeNewsWire
4 months ago
Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2024 on Tuesday, August 13, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024
Neutral
GlobeNewsWire
7 months ago
Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) --  Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences:
Mersana Therapeutics to Present at Upcoming Investor Conferences
Charts implemented using Lightweight Charts™